Find Dasabuvir Sodium manufacturers, exporters & distributors on PharmaCompass

Dasabuvir Sodium

PMC Dasabuvir Sodium

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

With Fermion, start the journey of your innovative API.

Contact Supplier

Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 2 Listed Suppliers

2 API Suppliers
2 Listed Suppliers

FINISHED DOSAGE FORMULATIONS

5 FDF Dossiers, 2 FDA Orange Book, 3 Europe

5 FDF Dossiers
2 FDA Orange Book
3 Europe

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 250MG BASE;12.5MG, 75MG, 50MG, TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

drugProductComposition
TABLET;ORAL - EQ 250MG BASE;12.5MG, 75MG, 50MG
TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Seqens, 1 PMC Isochem, 1 Bioplus Life Sciences

relatedExcipients
1 Seqens
1 PMC Isochem
1 Bioplus Life Sciences

EXCIPIENTS BY APPLICATIONS

2 Emulsifying Agents, 1 Film Formers & Plasticizers, 1 Solubilizers, 1 Topical, 1 Surfactant & Foaming Agents, 1 Thickeners and Stabilizers

excipientsByApplications
2 Emulsifying Agents
1 Film Formers & Plasticizers
1 Solubilizers
1 Topical
1 Surfactant & Foaming Agents
1 Thickeners and Stabilizers

DIGITAL CONTENT

30 NEWS #PharmaBuzz

media
30 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 Finished Drug Prices

globalSalesInformation
3 Finished Drug Prices

PATENTS & EXCLUSIVITIES

37 US Patents

patents
37 US Patents

Dasabuvir Sodium

Synopsis

ACTIVE PHARMA INGREDIENTS

2

API Suppliers

0

USDMF

0

CEP/COS

CEP/COS Certifications

0

JDMF

0

EU WC

0

KDMF

0

NDC API

0

VMF

2

Listed Suppliers

API REF. PRICE (USD/KG)

$

$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

5

FDF Dossiers

2

FDA Orange Book

FDA (Orange Book)

3

Europe

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

37

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

30

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

NA

Annual Reports (USD Million)

NA

Finished Drug Prices

3 RELATED EXCIPIENT COMPANIES

7EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Click the button for full data set

Also known as: 1132940-11-4, Dasabuvir sodium anhydrous, N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide sodium salt, Sodium (6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-2-methoxyphenyl)naphthalen-2-yl)(methylsulfonyl)amide, Chebi:85179, Q27158387

Molecular Formula

C₂₆H₂₆N₃NaO₅S

Molecular Weight

515.6 g/mol

InChI Key

VZCGKKLFRJCTFM-UHFFFAOYSA-N

Dasabuvir Sodium

1 2D Structure

Dasabuvir Sodium

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

sodium;[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]-methylsulfonylazanide

2.1.2 InChI

InChI=1S/C26H26N3O5S.Na/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18;/h6-15H,1-5H3,(H,27,30,31);/q-1;+1

2.1.3 InChI Key

VZCGKKLFRJCTFM-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C)(C)C1=CC(=CC(=C1OC)C2=CC3=C(C=C2)C=C(C=C3)[N-]S(=O)(=O)C)N4C=CC(=O)NC4=O.[Na+]

2.2 Synonyms

2.2.1 Depositor-Supplied Synonyms

1. 1132940-11-4

2. Dasabuvir Sodium Anhydrous

3. N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide Sodium Salt

4. Sodium (6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-2-methoxyphenyl)naphthalen-2-yl)(methylsulfonyl)amide

5. Chebi:85179

6. Q27158387

7. Sodium {6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-2-methoxyphenyl]naphthalen-2-yl}(methanesulfonyl)azanide

8. Sodium;[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]-methylsulfonylazanide

2.3 Create Date

2014-12-27

3 Chemical and Physical Properties

Molecular Formula	C₂₆H₂₆N₃NaO₅S
Molecular Weight	515.6 g/mol
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	6
Exact Mass	515.14908639 g/mol
Monoisotopic Mass	515.14908639 g/mol
Topological Polar Surface Area	102 Å²
Heavy Atom Count	36
Formal Charge	0
Complexity	944
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Indication

Exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.

For hepatitis C virus (HCV) genotype specific activity.

5 Pharmacology and Biochemistry

5.1 ATC Code

J05AP09

API SUPPLIERS

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - TABLET;ORAL - EQ 250MG BASE;12.5MG, ...DOSAGE - TABLET;ORAL - EQ 250MG BASE;12.5MG, 75MG, 50MG

USFDA APPLICATION NUMBER - 206619

DOSAGE - TABLET, EXTENDED RELEASE;ORAL - EQ 2...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

USFDA APPLICATION NUMBER - 208624

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Emulsifying Agents

Film Formers & Plasticizers

Solubilizers

Topical

Surfactant & Foaming Agents

Thickeners and Stabilizers

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

Global Sales Information

Do you need Business Intel? Ask us

Finished Drug Prices

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Market Place

Home

Menu

Post Enquiry

Market Place

Search